European Bone Marrow Transplant (EBMT) Patient and Family Day – Sat 6 April 2013

As part of the European Bone Marrow Transplant (EBMT) group’s annual conference, there will be a Patient and Family Day on Saturday 6 April 2013. The EBMT Annual Meeting is the most important annual event for research and education in the field of bone marrow transplantation in Europe and during the conference a special Patient and Family Day will be held for patients who have undergone a bone marrow transplant and their families.

Increased risk of myeloma in World Trade Center rescue workers

The results of the latest in a number of studies suggest that the people involved in the rescue and recovery operation following the September 11 attack at the World Trade Center are at an increased risk of developing myeloma and other cancers. Published in the December 2012 issue of the prestigious Journal of the American Medical Association, the study involved an analysis of the information collected from 55,778 people enrolled in the World Trade Center…

Study shows a decline in physical activity after myeloma diagnosis

An Australian study published in the journal Supportive Care in Cancer has revealed that levels of physical activity decline after patients are diagnosed with myeloma. The research surveyed 229 myeloma patients and found that participation in physical activity declined significantly from pre-diagnosis levels. Fatigue, injuries and pain were identified as the strongest perceived barriers to taking part. However, 41% of patients were willing to try an exercise programme if one was offered to them.

Pomalidomide shows survival benefit for myeloma patients

The latest results from an international Phase III clinical study, show that pomalidomide with low-dose dexamethasone improves the length of remission and extends overall survival in relapsed and refractory myeloma patients. Pomalidomide, an immunomodulatory drug (IMiD) similar to Revlimid® and derived from thalidomide, is being developed by the pharmaceutical company Celgene as a potential treatment in myeloma.

Subcutaneous Velcade® approved for use across Europe

MPE has welcomed the news today that the European Commission has approved a marketing licence for Velcade to be used as a subcutaneous (under the skin) injection for myeloma patients. Velcade was the first in a class of anti-cancer drugs called proteasome inhibitors to be used in myeloma. It was first licensed in Europe in an IV formulation and since then Velcade has had a significant impact on the treatment of myeloma.